Neurosense Therapeutics Ltd NRSN

$3.93 -0.12 (-2.96%)

Valuation

Market cap
7,682,000
Revenue TTM
$0
Net income TTM
$-11,130,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
24,200
Avg volume
25,201
Day's range
$3.82 – $4.01
Shares out
1,897,000
Stochastic %K
3%
Beta
1.66
Analysts
Strong Sell
Price target
$144.40

Price

Company profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyot...

Show more

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Industry
Biotechnology
Sector
Healthcare
Phone
972 9 799 6183
Website
https://www.neurosense-tx.com
Address
Building B, 11 HaMenofim Street, Herzliya, Israel

Latest news

Stocktwits

TwongStocks Oct 2, 8:21 PM
$NRSN NeuroSense Provides Update on Nasdaq Listing Compliance https://www.prnewswire.com/news-releases/neurosense-provides-update-on-nasdaq-listing-compliance-302897458.html • Since NRSN did not regain compliance with the MVLS requirement by Sept 29, Nasdaq determined that NRSN will be delisted unless NRSN requests an appeal of the Staff Determination. • Under Nasdaq's rules, a timely hearing request stays the suspension of the Company's securities and the filing of a Form 25-NSE. • The Panel has discretion to grant an exception of up to 180 days from the date of the Staff Determination. NRSN did regain compliance with the $1 bid price rule. The only outstanding issue is the MVLS requirement (minimum MVLS of at least $35M).
0 replies
boilerrm04 Oct 2, 6:49 PM
$NRSN Does this look like the face of someone concerned with delistment?
1 replies
Mulhollandr Oct 2, 4:26 PM
$CLNN $BCLI $NRSN $COYA If you didn’t follow her, you were missing out. Brooke handled her ALS journey with amazing grace and humor. RIP Brooke Eby
1 replies
PSM_EmpowerTrading Oct 2, 1:22 PM
🌅 Watchlist PART 2 ✅ $QTEX ideal above 1; above 1.20, potential to 1.50/.70 ✅ $TNMG 4.50 support, above 5, potential to 5.50/6 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $EZGO $NRSN still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N, not GR🥵🥵D
0 replies
AZOZ Oct 2, 1:03 PM
$NRSN Oversold Micro floter HI risk hi reward play Stay tuned 🛰️
0 replies
bin1adin Oct 1, 11:13 PM
$NRSN i dont get why they didnt just sue the big pharma that had them waiting and delayed their work and ontop of that probably ruined neurosense and prime c name in the health sector
0 replies
Zoofar Oct 1, 10:47 PM
$NRSN say it! say ”Zoofar was right” i want to hear it!!!
0 replies
Babilon1210 Oct 1, 8:08 PM
$NRSN
0 replies